Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2 Tower Place, Suite 2000 SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.standardbio.com |
IR: | See website |
Key People | ||
Tom Carey Chairman of the Board | Michael Egholm President, Chief Executive Officer, Director | Jeffrey G. Black Chief Financial Officer, Senior Vice President |
Hanjoon Alex Kim Chief Operating Officer | Shane Bowen Chief Technology Officer | Jeremy Davis Chief Commercial Officer | Adam Taich Chief Strategy Officer |
Business Overview |
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research. |
Financial Overview |
For the fiscal year ended 31 December 2023, Standard Biotools Inc revenues increased 9% to $106.3M. Net loss decreased 61% to $74.7M. Revenues reflect Proteomics segment increase of 22% to $63.9M, China segment increase of 40% to $15.8M, United States segment increase of 8% to $44.1M. Lower net loss reflects Loss on forward sale of Series B Preferr decrease from $60.1M (expense) to $0K, Loss on bridge loans decrease from $13.7M (expense) to $0K. |
Employees: | 534 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,271M as of Dec 31, 2023 |
Annual revenue (TTM): | $106.34M as of Dec 31, 2023 |
EBITDA (TTM): | -$47.86M as of Dec 31, 2023 |
Net annual income (TTM): | -$74.66M as of Dec 31, 2023 |
Free cash flow (TTM): | -$46.12M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 290,117,930 as of Feb 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |